Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Otsuka will pay up to $1.125 billion to acquire Jnana Therapeutics, gaining a first-in-class oral candidate for phenylketonuria that could compete with…
Otsuka Pharmaceutical said on Thursday it would acquire US biotechnology firm Jnana Therapeutics for up to $1.125 billion to bolster its rare disease pipeline.…
Repinatrabit (JNT-517) open-label-extension data in PKU show -67% mean blood Phe reduction in adolescents; pivotal Phase 3 PheORD design presented at ACMG 2026.
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Otsuka acquired Boston-based Jnana Therapeutics as a wholly owned subsidiary in an all-cash deal: $800M upfront plus up to $325M in development and regulatory milestones (headline value up to $1.125B). Announced August 1, 2024, the acquisition CLOSED on September 24, 2024, with Jnana becoming a direct subsidiary of Otsuka America, Inc. The deal centered on JNT-517 (now named repinatrabit), a first-in-class oral SLC6A19 inhibitor for phenylketonuria (PKU) that lowers blood phenylalanine independent of patient age or genotype, plus Jnana's RAPID (Reactive Affinity Probe Interaction Discovery) chemoproteomics platform feeding a specialty/autoimmune pipeline. Post-close the lead asset advanced as projected: Otsuka launched the global Phase 3 pivotal PheORD trial (NCT06971731, recruiting, started October 2025) and reported positive open-label-extension data at ACMG 2026 showing a ~67% mean reduction in blood Phe in adolescents, validating the original deal thesis.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd. / Jnana Therapeutics Inc. (this deal) | 2024 | $1.1B | — |
| Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc. | 2014 | $3.5B | 41 |
| Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc. | 2026 | $1.2B | — |
| Otsuka Pharmaceutical Co., Ltd. / 4D Molecular Therapeutics, Inc. | 2025 | $421M | — |
| Otsuka Pharmaceutical Co., Ltd. / Cantargia AB | 2025 | $613M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2024 deals · Otsuka Pharmaceutical Co., Ltd. deals · Immunology deals